Topic: Specialty Drugs

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Production Plus Profit Pricing (P-quad) FAQ

  • Medicare Must Study Unproven, Expensive Alzheimer’s Drug

  • Value-Based Management of Specialty Drugs: Practical Considerations and Implications for Pharmacy

  • The Drugs at the Heart of Our Pricing Crisis

  • Biosimilars: Market Changes do not equal policy success

  • Ethics of Clinical Trials to Evaluate Biosimilars

  • Bottom-Up Pricing Estimate for P-quad

  • Modeling P-quad

  • Time to Throw in the Towel on Biosimilars